PL2134702T3 - Krystaliczne postacie 6-[2-(metylokarbamoilo)fenylosulfanylo]-3-e-[2-(pirydyn-2-ylo)etenylo]indazolu przydatne w leczeniu nienormalnego wzrostu komórek u ssaków - Google Patents
Krystaliczne postacie 6-[2-(metylokarbamoilo)fenylosulfanylo]-3-e-[2-(pirydyn-2-ylo)etenylo]indazolu przydatne w leczeniu nienormalnego wzrostu komórek u ssakówInfo
- Publication number
- PL2134702T3 PL2134702T3 PL08719405T PL08719405T PL2134702T3 PL 2134702 T3 PL2134702 T3 PL 2134702T3 PL 08719405 T PL08719405 T PL 08719405T PL 08719405 T PL08719405 T PL 08719405T PL 2134702 T3 PL2134702 T3 PL 2134702T3
- Authority
- PL
- Poland
- Prior art keywords
- phenylsulfanyl
- methylcarbamoyl
- indazole
- ethenyl
- pyridin
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000010261 cell growth Effects 0.000 title 1
- WRSXUNSJGJUKHE-UHFFFAOYSA-N indazole Chemical compound C1=CC=C[C]2C=NN=C21 WRSXUNSJGJUKHE-UHFFFAOYSA-N 0.000 title 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 title 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91037907P | 2007-04-05 | 2007-04-05 | |
US97654607P | 2007-10-01 | 2007-10-01 | |
US3155408P | 2008-02-26 | 2008-02-26 | |
EP08719405.6A EP2134702B2 (en) | 2007-04-05 | 2008-03-25 | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals |
PCT/IB2008/000792 WO2008122858A2 (en) | 2007-04-05 | 2008-03-25 | Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals |
Publications (2)
Publication Number | Publication Date |
---|---|
PL2134702T3 true PL2134702T3 (pl) | 2017-10-31 |
PL2134702T5 PL2134702T5 (pl) | 2023-12-04 |
Family
ID=39831473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08719405.6T PL2134702T5 (pl) | 2007-04-05 | 2008-03-25 | Krystaliczne postacie 6-[2-(metylokarbamoilo)fenylosulfanylo]-3-e-[2-(pirydyn-2-ylo)etenylo]indazolu przydatne w leczeniu nienormalnego wzrostu komórek u ssaków |
Country Status (23)
Country | Link |
---|---|
US (1) | US8791140B2 (pl) |
EP (4) | EP4074702A1 (pl) |
JP (2) | JP5869197B2 (pl) |
KR (1) | KR101237588B1 (pl) |
CN (2) | CN103626739B (pl) |
AR (1) | AR065931A1 (pl) |
AU (1) | AU2008236444B2 (pl) |
BR (1) | BRPI0809471A2 (pl) |
CA (1) | CA2682859C (pl) |
CY (1) | CY1119119T1 (pl) |
DK (1) | DK2134702T4 (pl) |
ES (2) | ES2919351T3 (pl) |
FI (1) | FI2134702T4 (pl) |
HK (1) | HK1193405A1 (pl) |
IL (1) | IL201320A (pl) |
MX (1) | MX2009010761A (pl) |
NZ (1) | NZ580126A (pl) |
PL (1) | PL2134702T5 (pl) |
PT (1) | PT2134702T (pl) |
RU (1) | RU2518898C2 (pl) |
SI (1) | SI2134702T2 (pl) |
TW (1) | TWI481602B (pl) |
WO (1) | WO2008122858A2 (pl) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2134702T2 (sl) | 2007-04-05 | 2023-12-29 | Pfizer Products Inc. | Kristalinične oblike 6-(2-(metilkarbamoil)fenilsulfanil)-3-E-(2-(piridin-2-il)etenil)indazola primerne za zdravljenje abnormalne rasti celic pri sesalcih |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
JO3062B1 (ar) * | 2010-10-05 | 2017-03-15 | Lilly Co Eli | R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري |
RU2014107767A (ru) | 2011-09-30 | 2015-11-10 | Пфайзер Инк. | Фармацевтические композиции на основе n-метил-2-[3-((е)-2-пиридин-2-ил-винил)-1н-индазол-6-илсульфанил]бензамида |
MX2014005715A (es) | 2011-11-11 | 2014-05-28 | Pfizer | N-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]- benzamida para el tratamiento de leucemia mielogenosa cronica. |
WO2013105894A1 (en) | 2012-01-13 | 2013-07-18 | Xspray Microparticles Ab | A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
CN104230886A (zh) * | 2013-06-24 | 2014-12-24 | 南京华威医药科技开发有限公司 | 阿昔替尼新晶型 |
WO2015067224A1 (en) | 2013-11-08 | 2015-05-14 | Zentiva, K.S. | Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole |
CN104650034A (zh) * | 2013-11-22 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 一种稳定的阿西替尼化合物 |
CN105960415A (zh) | 2014-02-04 | 2016-09-21 | 辉瑞大药厂 | 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合 |
CN106458920B (zh) * | 2014-03-31 | 2019-02-15 | 千寿制药株式会社 | 炔基吲唑衍生物及其用途 |
US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
EP4279087A3 (en) | 2015-02-26 | 2024-01-31 | Merck Patent GmbH | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
WO2016178150A1 (en) * | 2015-05-05 | 2016-11-10 | Shilpa Medicare Limited | Novel polymorphs of axitinib |
AU2016280003B2 (en) | 2015-06-16 | 2021-09-16 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
TW201808910A (zh) | 2016-05-16 | 2018-03-16 | 帝人製藥股份有限公司 | 喹啉衍生物之結晶 |
KR20190062515A (ko) | 2016-10-06 | 2019-06-05 | 화이자 인코포레이티드 | 암의 치료를 위한 아벨루맙의 투약 용법 |
CN106883212A (zh) * | 2017-03-16 | 2017-06-23 | 合肥拓锐生物科技有限公司 | 一种xli晶型阿昔替尼的制备方法 |
US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
EA202193065A1 (ru) | 2019-05-09 | 2022-03-02 | Синтон Б.В. | Фармацевтическая композиция, содержащая акситиниб |
CN111187253B (zh) * | 2020-01-09 | 2023-05-09 | 鲁南制药集团股份有限公司 | 一种阿昔替尼新晶型 |
TW202202138A (zh) | 2020-03-25 | 2022-01-16 | 美商歐克萊製藥公司 | 含有酪胺酸激酶抑制劑之眼用植入物 |
WO2022000265A1 (zh) * | 2020-06-30 | 2022-01-06 | 天津理工大学 | 一种阿西替尼与戊二酸共晶及其制备方法 |
CN113943270B (zh) * | 2020-07-15 | 2023-05-09 | 鲁南制药集团股份有限公司 | 一种阿昔替尼晶型 |
CN113943271B (zh) * | 2020-07-15 | 2023-11-14 | 鲁南制药集团股份有限公司 | 一种阿昔替尼晶型及其制备方法 |
CN114685437B (zh) * | 2020-12-25 | 2022-12-09 | 鲁南制药集团股份有限公司 | 阿昔替尼与糖精共晶 |
CN114685436B (zh) * | 2020-12-25 | 2022-12-02 | 鲁南制药集团股份有限公司 | 阿昔替尼糖精共晶水合物 |
CN114685431B (zh) * | 2020-12-26 | 2022-11-29 | 鲁南制药集团股份有限公司 | 一种阿昔替尼柠檬酸盐晶型 |
CN114685435B (zh) * | 2020-12-28 | 2023-01-31 | 鲁南制药集团股份有限公司 | 阿昔替尼马来酸盐晶型及其制备 |
CN114685434B (zh) * | 2020-12-28 | 2023-06-16 | 鲁南制药集团股份有限公司 | 一种阿昔替尼与戊二酸共晶 |
CN114685432B (zh) * | 2020-12-28 | 2022-11-25 | 鲁南制药集团股份有限公司 | 阿昔替尼盐晶型及其制备方法 |
CN114685433B (zh) * | 2020-12-28 | 2022-11-25 | 鲁南制药集团股份有限公司 | 一种阿昔替尼香草酸共晶盐及其制备 |
WO2023166418A2 (en) | 2022-03-03 | 2023-09-07 | Pfizer Inc. | Multispecific antibodies and uses thereof |
EP4282415A1 (en) | 2022-05-26 | 2023-11-29 | Genepharm S.A. | A stable tablet composition of axitinib |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
US7141581B2 (en) * | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
CZ20022332A3 (cs) † | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sestava vzorků |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
RU2341263C2 (ru) | 2003-04-03 | 2008-12-20 | Пфайзер Инк. | Лекарственные формы, содержащие ag013736 |
CA2586176A1 (en) | 2004-11-02 | 2006-05-11 | Srinivasan Babu | Methods for preparing indazole compounds |
CN101094836A (zh) | 2004-11-02 | 2007-12-26 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
KR20070060145A (ko) | 2004-11-02 | 2007-06-12 | 화이자 인코포레이티드 | 6-[2-(메틸카바모일)페닐설파닐]-3-e-[2-(피리딘-2-일)에테닐]인다졸의 다형체 형태 |
CN101052633A (zh) | 2004-11-02 | 2007-10-10 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
MX2007005291A (es) * | 2004-11-02 | 2007-07-19 | Pfizer | Metodos para preparar compuestos de indazol. |
EP1885338A1 (en) | 2005-05-19 | 2008-02-13 | Pfizer, Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
SI2134702T2 (sl) * | 2007-04-05 | 2023-12-29 | Pfizer Products Inc. | Kristalinične oblike 6-(2-(metilkarbamoil)fenilsulfanil)-3-E-(2-(piridin-2-il)etenil)indazola primerne za zdravljenje abnormalne rasti celic pri sesalcih |
RU2014107767A (ru) † | 2011-09-30 | 2015-11-10 | Пфайзер Инк. | Фармацевтические композиции на основе n-метил-2-[3-((е)-2-пиридин-2-ил-винил)-1н-индазол-6-илсульфанил]бензамида |
-
2008
- 2008-03-25 SI SI200831821T patent/SI2134702T2/sl unknown
- 2008-03-25 EP EP22171745.7A patent/EP4074702A1/en not_active Withdrawn
- 2008-03-25 MX MX2009010761A patent/MX2009010761A/es active IP Right Grant
- 2008-03-25 RU RU2009136593/04A patent/RU2518898C2/ru active
- 2008-03-25 ES ES17168752T patent/ES2919351T3/es active Active
- 2008-03-25 PL PL08719405.6T patent/PL2134702T5/pl unknown
- 2008-03-25 EP EP17168752.8A patent/EP3252047B1/en active Active
- 2008-03-25 EP EP08719405.6A patent/EP2134702B2/en active Active
- 2008-03-25 ES ES08719405T patent/ES2634866T5/es active Active
- 2008-03-25 PT PT87194056T patent/PT2134702T/pt unknown
- 2008-03-25 NZ NZ580126A patent/NZ580126A/en unknown
- 2008-03-25 DK DK08719405.6T patent/DK2134702T4/da active
- 2008-03-25 BR BRPI0809471-3A patent/BRPI0809471A2/pt not_active Application Discontinuation
- 2008-03-25 CN CN201310662484.1A patent/CN103626739B/zh active Active
- 2008-03-25 KR KR1020097023066A patent/KR101237588B1/ko active IP Right Grant
- 2008-03-25 FI FIEP08719405.6T patent/FI2134702T4/fi active
- 2008-03-25 CN CN200880016453A patent/CN101679356A/zh active Pending
- 2008-03-25 CA CA2682859A patent/CA2682859C/en active Active
- 2008-03-25 US US12/594,575 patent/US8791140B2/en active Active
- 2008-03-25 AU AU2008236444A patent/AU2008236444B2/en active Active
- 2008-03-25 EP EP23167662.8A patent/EP4249063A3/en active Pending
- 2008-03-25 WO PCT/IB2008/000792 patent/WO2008122858A2/en active Application Filing
- 2008-04-03 JP JP2008096783A patent/JP5869197B2/ja active Active
- 2008-04-03 TW TW097112383A patent/TWI481602B/zh active
- 2008-04-03 AR ARP080101388A patent/AR065931A1/es not_active Application Discontinuation
-
2009
- 2009-10-01 IL IL201320A patent/IL201320A/en active IP Right Grant
-
2010
- 2010-06-09 HK HK14106750.1A patent/HK1193405A1/zh unknown
-
2014
- 2014-06-02 JP JP2014113765A patent/JP2014193900A/ja not_active Withdrawn
-
2017
- 2017-07-24 CY CY20171100790T patent/CY1119119T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1193405A1 (zh) | 適用於治療哺乳動物異常細胞生長的 甲基-氨甲酰基 苯基硫基 吡啶- -基 乙烯基 吲唑的晶型 | |
TWI369205B (en) | Sulfonyl amide derivatives for the treatment of abnormal cell growth | |
AP2008004488A0 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
PL2409727T3 (pl) | Urządzenia elektroporacyjne do elektroporacji komórek u ssaków | |
GB0709420D0 (en) | Machining process monitor | |
EP2182556A4 (en) | PROCESS FOR MANUFACTURING A SOLAR CELL | |
EP2257986A4 (en) | PROCESS FOR MANUFACTURING SOLAR CELLS | |
ZA201005208B (en) | Process for the manufacture of solar cells | |
PL2321295T3 (pl) | Pochodne 4-(pirydyn-4-ylo)-1H-[1,3,5]triazyn -2-onu jako inhibitory GSK2-beta do leczenia chorób degeneracyjnych | |
ZA200608394B (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
SI2173891T1 (sl) | Encimski proces za pridobivanje korteksolon-17-alfa-propionata v kristaliniäśni obliki iii | |
IL197695A0 (en) | 3-amino-pyridine derivatives for the treatment of metabolic disorders | |
EP2154242A4 (en) | METHOD FOR INDUCING MYOCARDIAL CELL DIFFERENTIATION USING G-CSF | |
GB0814443D0 (en) | Process for cultivating cells | |
EP2092054A4 (en) | METHOD FOR CONTROLLING THE GROWTH OF A CELL CULTURE | |
EP2424671A4 (en) | METHOD FOR CONTROLLING TREATMENT CONDITIONS IN REFINERS | |
EP2387402A4 (en) | METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS WITH 2,4-PYRIMIDINIAMIN COMPOUNDS | |
ZA200906990B (en) | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals | |
EP2172562A4 (en) | PROCESS FOR INTEGRATING NON-INVASIVE BACTERIA IN EUKARYOTIC CELLS | |
AU2008900382A0 (en) | Method for treating B cell disorders | |
IL244553B (en) | Altered placental cells | |
AU2007900771A0 (en) | Method and Apparatus for the Treatment of Abnormal Cell Structures | |
IL192452A (en) | A process for producing titanium salts | |
PL389673A1 (pl) | Nowe pochodne 1-(2-pirydylo)-6-podstawione imidazo [1, 2-a][1, 3, 5] triazyny oraz sposób ich wytwarzania | |
ZA201000159B (en) | Process for the production of substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof |